scholarly journals Integrative network analysis of TCGA data for ovarian cancer

2014 ◽  
Vol 8 (1) ◽  
Author(s):  
Qingyang Zhang ◽  
Joanna E Burdette ◽  
Ji-Ping Wang
Medicine ◽  
2020 ◽  
Vol 99 (41) ◽  
pp. e22549
Author(s):  
Mingyan Sheng ◽  
Haofei Tong ◽  
Xiaoyan Lu ◽  
Ni Shanshan ◽  
Xingguo Zhang ◽  
...  

2020 ◽  
Vol 13 (S9) ◽  
Author(s):  
Tianyu Zhang ◽  
Liwei Zhang ◽  
Fuhai Li

Abstract Background Though accounts for 2.5% of all cancers in female, the death rate of ovarian cancer is high, which is the fifth leading cause of cancer death (5% of all cancer death) in female. The 5-year survival rate of ovarian cancer is less than 50%. The oncogenic molecular signaling of ovarian cancer are complicated and remain unclear, and there is a lack of effective targeted therapies for ovarian cancer treatment. Methods In this study, we propose to investigate activated signaling pathways of individual ovarian cancer patients and sub-groups; and identify potential targets and drugs that are able to disrupt the activated signaling pathways. Specifically, we first identify the up-regulated genes of individual cancer patients using Markov chain Monte Carlo (MCMC), and then identify the potential activated transcription factors. After dividing ovarian cancer patients into several sub-groups sharing common transcription factors using K-modes method, we uncover the up-stream signaling pathways of activated transcription factors in each sub-group. Finally, we mapped all FDA approved drugs targeting on the upstream signaling. Results The 427 ovarian cancer samples were divided into 3 sub-groups (with 100, 172, 155 samples respectively) based on the activated TFs (with 14, 25, 26 activated TFs respectively). Multiple up-stream signaling pathways, e.g., MYC, WNT, PDGFRA (RTK), PI3K, AKT TP53, and MTOR, are uncovered to activate the discovered TFs. In addition, 66 FDA approved drugs were identified targeting on the uncovered core signaling pathways. Forty-four drugs had been reported in ovarian cancer related reports. The signaling diversity and heterogeneity can be potential therapeutic targets for drug combination discovery. Conclusions The proposed integrative network analysis could uncover potential core signaling pathways, targets and drugs for ovarian cancer treatment.


Author(s):  
LI CHEN ◽  
JIANHUA XUAN ◽  
JINGHUA GU ◽  
YUE WANG ◽  
ZHEN ZHANG ◽  
...  

2020 ◽  
Author(s):  
tiefeng cao ◽  
huimin shen

Abstract Background:Chemotherapeutic resistance is responsible for treatment failure. Immunotherapy is important in ovarian cancer (OC). Systematic exploration of immunogenic landscape and reliable immune gene-based prognostic biomarkers or signature is necessary to be identified. This study aims to identify the immune gene-based prognostic biomarkers and regulatory factors, further to develop an individualized prediction signature.Methods: This study systematically explored the gene expression profiles from RNA-seq data set for The Cancer Genome Atlas (TCGA) ovarian cancer. Differentially expressed and survival-associated immune genes and transcription factors (TFs) were identified using immune genes from ImmPort dataset and TFs from Cistoma database. We developed the prognostic signature based on survival associated immune genes with LASSO (Least absolute shrinkage and selection operator) Cox regression analysis. Further, Network analysis was performed to uncover the potential molecular mechanisms of immune-related genes with the help of computational biology. Results: The prognostic signature, a weighted combination of the 21 immune-related genes, performed moderately in survival prediction with AUC was 0.746, 0.735, and 0.749 for 1, 3, and 5 year overall survival, respectively. Network analysis uncovered the regulatory role of TFs in immune genes. Intriguingly, the prognostic signature reflected infiltration of some immune cell subtypes.Conclusions: We first constructed a signature with 21 immune genes of clinical significance, which showed promising predictive value in the surveillance, prognosis, even immunotherapy response of OC patients.


2020 ◽  
Vol 8 (1) ◽  
pp. e001126
Author(s):  
Catherine E Cioffi ◽  
K M Venkat Narayan ◽  
Ken Liu ◽  
Karan Uppal ◽  
Dean P Jones ◽  
...  

IntroductionBody fat distribution is strongly associated with cardiometabolic disease (CMD), but the relative importance of hepatic fat as an underlying driver remains unclear. Here, we applied a systems biology approach to compare the clinical and molecular subnetworks that correlate with hepatic fat, visceral fat, and abdominal subcutaneous fat distribution.Research design and methodsThis was a cross-sectional sub-study of 283 children/adolescents (7–19 years) from the Yale Pediatric NAFLD Cohort. Untargeted, high-resolution metabolomics (HRM) was performed on plasma and combined with existing clinical variables including hepatic and abdominal fat measured by MRI. Integrative network analysis was coupled with pathway enrichment analysis and multivariable linear regression (MLR) to examine which metabolites and clinical variables associated with each fat depot.ResultsThe data divided into four communities of correlated variables (|r|>0.15, p<0.05) after integrative network analysis. In the largest community, hepatic fat was associated with eight clinical biomarkers, including measures of insulin resistance and dyslipidemia, and 878 metabolite features that were enriched predominantly in amino acid (AA) and lipid pathways in pathway enrichment analysis (p<0.05). Key metabolites associated with hepatic fat included branched-chain AAs (valine and isoleucine/leucine), aromatic AAs (tyrosine and tryptophan), serine, glycine, alanine, and pyruvate, as well as several acylcarnitines and glycerophospholipids (all q<0.05 in MLR adjusted for covariates). The other communities detected in integrative network analysis consisted of abdominal visceral, superficial subcutaneous, and deep subcutaneous fats, but no clinical variables, fewer metabolite features (280, 312, and 74, respectively), and limited findings in pathway analysis.ConclusionsThese data-driven findings show a stronger association of hepatic fat with key CMD risk factors compared with abdominal fats. The molecular network identified using HRM that associated with hepatic fat provides insight into potential mechanisms underlying the hepatic fat–insulin resistance interface in youth.


2019 ◽  
Vol 29 (3) ◽  
pp. 550-556
Author(s):  
Anne Brédart ◽  
Julia Dick ◽  
Alejandra Cano ◽  
Léonore Robieux ◽  
Antoine De Pauw ◽  
...  

2006 ◽  
Vol 14 (7S_Part_19) ◽  
pp. P1016-P1017
Author(s):  
Burcu F. Darst ◽  
Qiongshi Lu ◽  
Rebecca L. Koscik ◽  
Erin Jonaitis ◽  
Lindsay R. Clark ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document